KROS · NASDAQ
Keros Therapeutics, Inc.
$9.45 -1.40 (-12.90%)
Company overview
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 for the treatment of anemia, which is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $187M
- Employees
- 163
- Headquarters
- Lexington, MA
- Website
- kerostx.com
- CEO
- Jasbir S. Seehra
- Listed
- April 8, 2020
- P/E
- -3.87
- Dividend yield
- 0.00%
Company financials
- Revenue
- $33.2M
- Gross profit
- $32M
- Operating income
- -$110M
- EBITDA
- -$95.2M
- Net income
- -$85.1M
- EPS
- -$2.44
- Total assets
- $312M
- Total debt
- $16.3M
- Gross margin
- 96.48%
- Net margin
- -256.60%
- Earnings yield
- -25.82%
No geographic segmentation.
Showing FY 2025
KROS
1D
NASDAQ
O11.13H11.22L10.80C10.830.00 (0.00%)Vol128.26K
News